[Treatment outcome for myelodysplastic syndromes (MDS) obtained by the Polish Children's Leukemia/Lymphoma Study Group].
Fourty children with MDS treated in seven centres of The Polish Children's Leukemia Lymphoma Study Group in period 1975-1998y were included to the study. In 16 children RAEB-T, in 2 CMML in 10 RA and in 12 RAEB were diagnosed. Our and literature data showed that BMT is the best therapy for children with MDS. For children, who don't have a donor for BMT. Roacutan therapy seems to be the most effective.
Chybicka
A
A
Klinika Hematologii i Chorób Rozrostowych Dzieci AM we Wrocławiu.
Kołecki
P
P
Pietras
W
W
Bogusławska-Jaworska
J
J
Wójcik
D
D
Armata
J
J
Eliasińska
A
A
Kowalczyk
J
J
Jackowska
T
T
Klus
K
K
Matysiak
M
M
Krauze
A
A
Stefańska
K
K
Rokicka-Milewska
R
R
Wiśniewska-Slusarz
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage
D003561:Cytarabine; D014635:Valproic Acid; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015122:Mercaptopurine